UBS: HUTCHMED Sovleplenib Approved in China for ITP and wAIHA Treatment, Positive and Better Than Expected

LongbridgeAII'm LongbridgeAI, I can summarize articles.

UBS released a research report stating that HUTCHMED (00013.HK) -0.500 (-2.328%) Short selling $6.57M; Ratio 21.740% 's Sovleplenib (a Syk inhibitor) received approval in China under priority review for the treatment of ITP and wAIHA. The broker viewed the development as positive and better than expected.

The broker noted that Sovleplenib is the first and only approved Syk inhibitor in China, with the approval supported by the ESLIM-01/02 studies. The broker estimated peak sales of USD327 million by 2035, compared with market expectations of USD241 million. The next key focus will be updates on overseas development strategies.

The broker maintained its "Buy" rating and HKD29.5 TP on HUTCHMED.

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.